Evidence map›Paper›PMID 23482590›Full record

Trial reportEuropean journal of endocrinology2013

The pharmacokinetics of acyl, des-acyl, and total ghrelin in healthy human subjects.

Jenny Tong, Nimita Dave, Ganesh M Mugundu, Harold W Davis, Bruce D Gaylinn, Michael O Thorner, Matthias H Tschöp, David D'Alessio, Pankaj B Desai

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in European journal of endocrinology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Beyond Hunger: The Structure, Signaling, and Systemic Roles of Ghrelin.International journal of molecular sciences · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jenny TongDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio 45219-0547, USA. jenny.tong@uc.edu
Nimita Dave
Ganesh M Mugundu
Harold W Davis
Bruce D Gaylinn
Michael O Thorner
Matthias H Tschöp
David D'Alessio
Pankaj B Desai
University of Cincinnati · USUniversity of Cincinnati Medical Center · USUniversity of Virginia · US

Funding

Cincinnati Center for Clinical and Translational Sciences and TrainingUL1TR000077 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., TSEVAT, JOEL · 2012 to 2014
$9.9M
Ghrelin Regulation: Implications for Understanding ObesityR01DK076037 · NIDDK · UNIVERSITY OF VIRGINIA · PI THORNER, MICHAEL O · 2008 to 2012
$2.7M
Impact of Ghrelin of Beta-cell Function and Insulin Sensitivity in HumansK23DK080081 · NIDDK · UNIVERSITY OF CINCINNATI · PI TONG, JENNY · 2007 to 2011
$865k
The Impact of Unacylated Ghrelin on Insulin Secretion and Glucose Tolerance in HuR03DK089090 · NIDDK · UNIVERSITY OF CINCINNATI · PI TONG, JENNY · 2010 to 2011
$156k
NCATS NIH HHS 8 UL1 TR000077-04NCATS NIH HHS UL1 TR000077NIDDK NIH HHS 1R03DK89090NIDDK NIH HHS 5K23DK80081NIDDK NIH HHS K23 DK080081NIDDK NIH HHS R01 DK076037NIDDK NIH HHS R03 DK089090
6 · The paper itself

Abstract

backgroundGhrelin stimulates GH secretion and regulates energy and glucose metabolism. The two circulating isoforms, acyl (AG) and des-acyl (DAG) ghrelin, have distinct metabolic effects and are under active investigation for their therapeutic potentials. However, there is only limited data on the pharmacokinetics of AG and DAG.

objectivesTo evaluate key pharmacokinetic parameters of AG, DAG, and total ghrelin in healthy men and women.

methodsIn study 1, AG (1, 3, and 5 μg/kg per h) was infused over 65 min in 12 healthy (8 F/4 M) subjects in randomized order. In study 2, AG (1 μg/kg per h), DAG (4 μg/kg per h), or both were infused over 210 min in ten healthy individuals (5 F/5 M). Plasma AG and DAG were measured using specific two-site ELISAs (study 1 and 2), and total ghrelin with a commercial RIA (study 1). Pharmacokinetic parameters were estimated by non-compartmental analysis.

resultsAfter the 1, 3, and 5 μg/kg per h doses of AG, there was a dose-dependent increase in the maximum concentration (C(max)) and area under the curve (AUC(0-last)) of AG and total ghrelin. Among the different AG doses, there was no difference in the elimination half-life, systemic clearance (CL), and volume of distribution. DAG had decreased CL relative to AG. The plasma DAG:AG ratio was ~2:1 during steady-state infusion of AG. Infusion of AG caused an increase in DAG, but DAG administration did not change plasma AG. Ghrelin administration did not affect plasma acylase activity.

conclusionsThe pharmacokinetics of AG and total ghrelin appears to be linear and proportional in the dose range tested. AG and DAG have very distinct metabolic fates in the circulation. There is deacylation of AG in the plasma but no evidence of acylation.

Indexed as

AdolescentAdultFemaleGhrelinHumansMaleMiddle AgedYoung AdultGhrelinghrelin, des-n-octanoyl

Identifiers

PMID23482590
PMCPMC3740531
OpenAlexW2108901938

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.